Navigation Links
DOR BioPharma to Present at the Rodman & Renshaw Annual Global Investor Healthcare Conference
Date:9/3/2009

ical trial of DOR201 in radiation enteritis in the second half of 2009. orBec(R) is also currently the subject of an NIH-supported, Phase 2, randomized, double-blind, placebo-controlled trial in the prevention of acute GVHD. Oral BDP may also have application in treating other gastrointestinal disorders characterized by severe inflammation. Additionally, DOR has a Lipid Polymer Micelle (LPM(TM)) drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis.

Through its Biodefense Division, DOR is developing biomedical countermeasures pursuant to the Project BioShield Act of 2004. DOR's biodefense products in development are recombinant subunit vaccines designed to protect against the lethal effects of exposure to ricin toxin and botulinum toxin. DOR's ricin toxin vaccine, RiVax(TM), has been shown to be well tolerated and immunogenic in a Phase 1 clinical trial in normal volunteers.

For further information regarding DOR BioPharma, Inc., please visit the Company's website at www.dorbiopharma.com.

This press release contains forward-looking statements that reflect DOR BioPharma, Inc.'s current expectations about its future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes," "intends," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. DOR cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including DOR201, orBec(R) and LPM(TM), particularly in light of the significant uncertainty inherent in developing vacci
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Eiger BioPharmaceuticals Appoints Paul Truex to Board of Directors
2. DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments
3. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
5. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
6. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
7. PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
8. Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology
9. Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities
10. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
11. DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Hartford, CT (PRWEB) July 30, 2014 ... economic development organization based in East Hartford, Conn., was ... on Phase II of a project that will determine ... facility in rural north-central Connecticut. USDA Rural Development provided ... (RBEG) program for the second phase of the feasibility ...
(Date:7/30/2014)... Arlington, MA (PRWEB) July 30, 2014 ... products, announces completion of its first round of seed ... round will enable preliminary efforts to develop a novel ... the support of our investors and their commitment to ... CEO of LayerBio. "Ophthalmology is one of many areas ...
(Date:7/29/2014)... The advanced optical methods and applications for ... a revolution in the neurosciences were the inspiration behind ... SPIE, the international society for optics and photonics ... of the BRAIN Initiative in the United States, and ... vision for and provide examples of the impact that ...
(Date:7/29/2014)... foam of atom-thick sheets can be made to any ... Rice University. , In microscopic images, the foam ... and walls that reinforce each other. The structure consists ... of graphene oxide that self-assemble with the assistance of ... the foam could find use in structural components, as ...
Breaking Biology Technology:USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 2SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 4Tough foam from tiny sheets 2
... 2012  Argos Therapeutics Inc., today announced that it ... AGS-003-006, a Phase 2 study of its Arcelis™ ... with advanced renal cell carcinoma (RCC). The results ... T cell responses and overall survival. AGS-003 in ...
... DIEGO, Jan. 31, 2012  bioTheranostics, Inc., a bioMerieux ... drive personalized treatment, has introduced a new product ... resistance and pathway interrogation called PRECIS Precision Medicine ... cancer management, partners accurate diagnosis of primary tumor ...
... science world, with the potential to create foldaway mobile phones, ... new finding at the University of Manchester gives graphene,s potential ... for distilling alcohol. In a report published in ... shows that graphene-based membranes are impermeable to all gases and ...
Cached Biology Technology:Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC) 2Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC) 3bioTheranostics Launches Precision Medicine Biomarkers for Tumor Pathway Interrogation 2bioTheranostics Launches Precision Medicine Biomarkers for Tumor Pathway Interrogation 3Supermaterial goes superpermeable 2
(Date:7/30/2014)... changing climate threaten some of the world,s most ... establish seed collections to save the seeds in ... some genetic diversity., For decades, these seed collections ... a one-size-fits-all approach for how many seeds to ... regardless of species, pollination mode, growth habitat and ...
(Date:7/30/2014)... from Bjorn Brembs, professor of neurogenetics at the Institute ... figure allowing readers and reviewers to run the underlying ... important leap forward for scientific publishing, by demonstrating a ... scholarly output. , Figure 3 in fact doesn,t really ... to F1000Research , and the figure is generated ...
(Date:7/30/2014)... injury (SCI), traumatic brain injury (TBI) and peripheral nerve ... learned over the past 30 years regarding both the ... growth, but this large body of information has not ... his team from University of Miami in USA proposed ... consensus is emerging that one contributing factor is a ...
Breaking Biology News(10 mins):Saving seeds the right way can save the world's plants 2F1000Research brings static research figures to life 2
... Hagfish is a strange animal: it feeds by gnawing its way ... 3 days. Scientists at the University of British Columbia (Canada) believe ... inside the carcass to become acidic from the build up of ... is able to cope with environmental conditions of up to 7% ...
... to a low-weight preemie at 24 weeks, exhibited the first-found ... and the amniotic fluid of a woman in preterm labor. ... cannot be cultured and grown in the lab, researchers from ... Department of Obstetrics and Gynecology at MetroHealth Medical Center in ...
... Dr. Peter Sarnow and a team of Stanford University scientists ... named miR-122, in order to replicate in cultured liver cells. ... amount of hepatitis C virus RNA was reduced by approximately ... potential to develop new antiviral agents against hepatitis C, the ...
Cached Biology News:Prenatal nicotine exposure reduces breathing response of newborns... 2Prenatal nicotine exposure reduces breathing response of newborns... 3
Multi-enzyme complex containing a wide range of carbohydrases, including arabanase, cellulase,b-glucanase, hemi-cellulase and xylanase Patent/trademark/license (electronic): A product of Novozyme Cor...
... Biotin Streptavidin-HRP Systems provide rapid, precise ... antigens in frozen or paraffin-embedded tissue, ... systems also facilitate double or triple ... performed simultaneously with primary antibodies of ...
Miscellaneous: Versatile stain for staining RNA (bluish-purple), DNA (blue), proteins (red) and acid polysaccharides Assay: ~ 95 % Suitab tst: differential staining of nucleic acids and prote...
Screening test for the detection of Salmonella sp. by means of DNA amplification, subsequent molecular hybridization and detection on a microtitre plate....
Biology Products: